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The FMS-like tyrosine kinase 3 (FLT3) mutation in acute myeloid leukemia (AML) is a nega-
tive prognostic factor and, in these cases, allogeneic stem cell transplantation (allo-SCT) can
represent an important therapeutic option, especially if performed in complete remission
(CR). However, it is increasingly clear that not all cytological CRs (cCRs) are the same and
that minimal residual disease (MRD) before allo-SCT could have an impact on AML outcome.
Unfortunately, FLT3, due its instability of expression, is still not considered a good molecular
MRD marker. We analyzed the outcome of allo-SCT in a population of FLT3-positive AML
patients according to molecular MRD at the pretransplantation workup, assessed by the
quantitative expression evaluation of the panleukemic marker Wilms’ tumor (WT1) gene.
Sixty-two consecutive AML FLT3-positive patients received allo-SCT between 2005 and
2016 in our center. The median age at transplantation was 55 years. The quantitative analysis
of the WT1 gene expression (bone marrow samples) was available in 54 out of 62 (87%) cases,
both at diagnosis (100% overexpressing WT1 with a mean of 9747 ± 8064 copies) and before
allo-SCT (33 WT1-negative and 21 WT1-positive cases at the pretransplantation workup). Of
these cases, 33/54 (61%) were both in cCR and molecular remission (WT1-negative) at the
time of transplantation, 13/54 (24%) were in cCR but not in molecular remission (WT1-
positive), and 8/54 (15%) showed a cytological evidence of disease (relapsed or refractory).
Both post-allo-SCT overall survival (OS) and disease-free survival (DFS) were significantly
better in patients who were WT1-negative (WT1 !250 copies) at the time of transplantation
compared with those who were WT1-positive (WT1O250 copies), with a median OS and DFS
not reached in the WT1-negative group and 10.2 and 5.5 months, respectively, in the
WT1-positive group (OS log–rank p[ 0.0005; hazard ratio [HR] [ 3.7, 95% confidence in-
terval [95% CI][ 1.5–9; DFS log–rank p[ 0.0001; HR[ 4.38, 95% CI[ 1.9–10). Patients
with cCR who were WT1-positive had the same negative outcome as those with a cytological
evidence of disease. The relapse rate after allo-SCT was 9% (3/33) in pre-allo-SCT WT1-
negative cases and 54% (7/13) in WT1-positive cases (p [ 0.002). At multivariate analysis,
WT1 negativity before allo-SCT and grade !2 acute graft versus host disease were the
only independent prognostic factors for improved OS and DFS. These data show that
pre-allo-SCT molecular MRD evaluation through WT1 expression is a powerful predictor
of posttransplantation outcomes (OS, DFS, relapse rate). Patients with both cCR and a
WT1-negative marker before allo-SCT have a very good outcome with very low relapse
rate; conversely, patients with positive molecular MRD and refractory/relapsed patients
have a negative outcome. The WT1 MRD stratification in FLT3-positive AML is a valuable
tool with which to identify patients who are at high risk of relapse and that could be consid-
ered from post-allo-SCT prophylaxis with FLT3 inhibitors or other strategies (donor lympho-
cyte infusion, tapering of immunosuppression, azacitidine). Copyright ! 2017 ISEH -
International Society for Experimental Hematology. Published by Elsevier Inc.
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The FMS-like tyrosine kinase 3 (FLT3) gene, located on
chromosome 13, encodes a tyrosine kinase receptor located
on the surface of hematopoietic progenitor cells that is
essential for cellular survival and differentiation [1–3].
FLT3 mutations can involve the receptor juxtamembrane
internal tandem duplication (ITD) domain or the intracel-
lular tyrosine kinase domain (TKD) and can cause, in
most cases, an autophosphorylation with the constitutive
activation of the receptor, resulting in a higher proliferation
and an increased survival of leukemic cells [1,3,4]. FLT3
mutations are present in 20–30% of acute myeloid leuke-
mia (AML) cases in adults and are associated with a high
risk of relapse and a poor prognosis [5–8]. Allogeneic
stem cell transplantation (allo-SCT) is an important thera-
peutic strategy in AML with unfavorable prognostic fac-
tors, as well as in FLT3-mutated AML [9].
Even though there exists much data supporting allo-SCT
in FLT3-positive patients, in this context, it is still neces-
sary to define risk subcategories (with different transplanta-
tion efficacy) based on FLT3-related (such as the FLT3
allelic burden) and FLT3-unrelated parameters (such as
the presence of other pretransplantation predictive factors)
[8,10–16].
We have analyzed the FLT3-mutated AML cases treated
with allo-SCT at our institution’s department of hematology
in the last 11 years (2005–2016) to identify clinical or bio-
logical variables (other than FLT3) that might predict post-
SCT outcome in this specific high-risk AML group.
Methods
The study population included 62 adult AML patients (over
18 years old) with FLT3 mutation at diagnosis who underwent
allo-SCT at the Udine Hospital Department of Hematology from
January 2005 to March 2016.
FLT3 mutational analyses (ITD and TKD) were performed ac-
cording to the method described by Gale and colleagues [10] based
on RNA extraction from bone marrow samples using automated
protocols (RNA mini kit/QiaCube, Qiagen, Europe), a subsequent
reverse transcription to cDNA using the random hexamers tech-
nique, and a multiplex polymerase chain reaction (PCR) able to
determine both the ITD and TKD mutations in the same reaction.
The primers used for the ITD mutations detection were juxtaposed
to the coding region of juxtamembrane domain, whereas the TKD
mutations were determined by the inclusion of a restriction enzyme
(EcoRV, Amersham International, UK) and subsequent digestion of
amplicons. The PCR products and the EcoRV digestion were then
separated via standard electrophoresis (qualitative assessment) or
by capillary gel electrophoresis performed using a genetic analyzer
(AB3500 DX, Applied Biosystems, Europe) and the obtained elec-
tropherogramswere analyzedwith Genescan software, allowing the
determination of the length of amplicons and their relative concen-
tration by fluorescence intensity [10,17].
Wilms’ tumor 1 (WT1) gene quantitative analysis was per-
formed on bone marrow samples using the real-time quantitative
PCR method. The WT1 ProfileQuant (Ipsogen, Marseille, France)
kit, standardized according to the European Leukemia Net guide-
lines, was used for this analysis [18]. Primers and probes were
localized on exons 1 and 2. The WT1 transcript values obtained
were normalized with respect to the number of ABL transcripts
(control gene) and expressed as WT1 copy number every 104
copies of ABL (WT1/ABL ! 104). The cut-off for bone marrow
samples was 250 WT1 copies/104 ABL copies, as reported by
Leukemia NET [18].
The cytological disease status at transplantation was evaluated
according to National Cancer Institute criteria and the subsequent
international working group review [19]. Cytological complete
remission (cCR) was defined as the absence of or !5% blastic
cells in the marrow, polymorphonuclear neutrophil (PMN) cell
numberO1 ! 109/L, plateletsO100 ! 109, and transfusion inde-
pendence. Partial remission (PR) was defined as a blast cell per-
centage in the marrow ranging between 5% and 15% in the
presence of an appropriate cellularity and signs of trilinear cell
regeneration. Patients who did not meet cCR or PR criteria were
defined as being resistant (RES) or nonresponders (NRs).
The molecular cytogenetic risk at diagnosis was defined ac-
cording to the European Leukemia Net classification [20]. Comor-
bidity index at the time of transplantation was calculated
according to Sorror criteria and scores [21].
The European Society for Blood and Marrow Transplantation
(EBMT) risk score was calculated as established by Gratwohl,
considering the following parameters at the time of transplanta-
tion: age, stage of disease (early, intermediate, late), interval
from diagnosis to transplantation (!12 months), type of donor,
and donor–recipient combination (sex) [22]. Graft versus host dis-
ease (GVHD) was diagnosed and staged according to Przepiorka
and Filipovich criteria [23,24]. None of the analyzed patients
received a FLT3 inhibitor before or after transplantation.
Statistical analysis
Continuous variables were analyzed using descriptive statistical
methods (arithmetic mean, standard deviation, median, range,
minimum, maximum). Categorical variables were compared
with chi-square test (two-tailed); p # 0.05 was considered statis-
tically significant. Multivariate analysis was performed using Cox
regression. Survival curves were constructed with the Kaplan–Me-
ier method and compared, where indicated, with the log–rank test.
Posttransplantation OS was calculated as the period (in months)
from the time of transplantation to last follow-up or death from
any cause. Posttransplantation DFS was defined as the period (in
months) from the reinfusion to posttransplantation relapse or
death. Patients who did not relapse were censored at the time of
death or at last follow-up. Estimation of relapse probability was
performed using the proper estimation of cumulative incidence
curves. The follow-up is updated to July 15, 2016. Data were
analyzed with MedCalc software (version 12.5.0.0; MedCalc Soft-
ware bvba, Ostend, Belgium).
Results
Patient characteristics
Thirty-five percent of the 62 patients with FLT3-mutated
AML who received transplantations at our department of
hematology from 2005 to 2016 were 60 years old or older.
The cytogenetic–molecular risk at diagnosis was: adverse
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and intermediate in 17% and 83% of cases, respectively;
81% of the patients (50/62) had an ITD FLT3 mutation,
17% (11/62) had a TKD mutation, and 2% (1 case) had
both mutations.
The quantitative analysis of the WT1 gene expression
was available in 54/62 (87%) cases at baseline, whereas
WT1 was not evaluated in eight cases. WT1 was overex-
pressed in all evaluable patients (54/54; 100%), with a
mean of 97476 8064 copies and a median of 7493.5 copies
(range, 454–33563). Eighty-four percent (52/62) of the pa-
tients were in cCR at the time of transplantation (48 in first
cCR and four in second cCR) and 16% (10/62) had an
active disease, either relapsed or RES. Patient characteris-
tics at baseline are shown in Table 1. Patient characteristics
at the time of transplantation are shown in Table 2.
Transplantation characteristics
The mean period of time between diagnosis and allo-SCT
was 7.4 6 5 months, with a median of 6 months (range,
3–28). The transplantation comorbidity index was: 0–1 in
31% of cases (19/62), 2 in 21% of cases (13/62), 3 in
33% of cases (21/62), and 4–6 in 15% of cases (9/62).
The EBMT risk score was: 1–2 in 32% of patients (20/
62), 3–4 in 53% (33/62) of cases, and 5–6 in 15% (9/62)
of cases. According to the type of donor, 28/62 (45%)
received a matched unrelated donor allo-SCT, 27/62
(43%) a sibling allo-SCT, 6/62 (10%) a mismatched SCT,
and 1/62 (2%) a SCT from cord blood. Bone marrow was
the stem cell source in 23/62 (37%) cases and peripheral
blood in the remaining 39/62 (63%) cases. Conditioning
regimen was myeloablative in 71% (44/62) of patients
and not myeloablative in the other 29% (18/62) (Table 2).
Outcome after allo-SCT
After a mean follow-up of 39 6 40 months (median,
18 months; range, 1–130), 55% (34/62) of the patients
were alive (31/34 in cCR) and 45% (28/62) were deceased.
Transplantation-related mortality (TRM) was 23% (14/62
cases). The primary causes of death were relapsed/refrac-
tory AML (14/28 cases) and TRM (14/28 cases). The
causes of death from TRM were: acute (aGVHD) or
chronic (cGVHD) GVHD in seven cases, bacterial or
fungal infections in seven cases, myocardial infarction in
one case, and esophageal carcinoma in one case. Death
from TRM occurred within 90 days after allo-SCT in 5/
14 patients, between 90 days and 1 year in 4/14 patients,
and O1 year after transplantation in the remaining 5/14
cases (Table 3).
aGVHD occurred within the first 3 months after trans-
plantation in 35/62 patients (56%), with a prevalence of
grade I–II GVHD (27/35 cases), whereas 8/35 (23%) cases
were of grade III or higher. cGVHD was documented in 12
of 51 evaluable cases (24%).
The median post-SCT survival of the study population
was 79 months, with an OS probability of 70% and 62%
at 12 and 36 months, respectively (Fig. 1A). The median
DFS was 58 months, with a DFS probability of 63% at
12 months and 57% at 36 months (Fig. 1B). In univariate
analysis, the nine patients with an EBMT score of 5–6
had a worse post-allo-SCT OS compared with the 53 pa-
tients with a score !4 (OS at 12 months: 25% vs 76%,
respectively; log–rank, p 5 0.001).
Table 1. Patient characteristics
Total Number 62
Sex (F/M) 36/26
Age, Mean 6 SD 51 6 12.24
Age, Median (range) 55 (20–69)
Molecular-Cytogenetic Risk
Adversea 11/62 (17%)
Intermediate (I and II) 51/62 (83%)
FLT3 Mutational Status
FLT3 ITD-Positive 50/62 (81%)
FLT3 D835-Positive 11/62 (17%)
FLT3 ITD-Positive and D835-Positive 1/62 (2%)
WT1 at Diagnosis
Available 54/62 (87%)
Not Available 8/62 (13%)
WT1 Overexpression (O250 copies) 54/54 (100%)
Copies, Mean 6 SD 9747 6 8064
Copies, Median (range) 7493.5 (454–33563)
FLT3 5 FMS-like tyrosine kinase 3; SD 5 standard deviation;
WT1 5 Wilms’ tumor.
a8/11 complex karyotype, 3/11 del 7.
Table 2. Patient characteristics at the time of allo-SCT
Age O60 Years at Transplantation 22/62 (35%)
Age !60 Years at Transplantation 40/62 (65%)
Disease Status
AML Relapsed/Refractory 10/62 (16%)
AML CR 52/62 (84%)
First CR 48/52 (92%)
Second CR 4/52 (8%)
EBMT Risk Score
1–2 20/62 (32%)
3–4 33/62 (53%)
5–6 9/62 (15%)
Comorbidity Index
0–1 19/62 (31%)
2 13/62 (21%)
3 21/62 (33%)
4 6/62 (10%)
5–6 3/62 (5%)
Type of Donor
Matched Unrelated Donor 28/62 (45%)
Sibling 27/62 (43%)
Mismatched 6/62 (10%)
Cord Blood 1/62 (2%)
Conditioning Regimen
Myeloablative 44/62 (71%)
Not Myeloablative 18/62 (29%)
Diagnosis allo-SCT (Months)
Mean 6 SD 7.4 6 5
Median (Range) 6 (3–28)
allo-SCT 5 allogeneic stem cell transplantation; AML 5 acute myeloid
leukemia; CR 5 complete remission; EBMT 5 European Society for
Blood and Marrow Transplantation; SD 5 standard deviation.
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Pre-allo-SCT WT1 evaluation and post-allo-SCT
outcome
Fifty-four of the 62 patients (87%) had a quantitative WT1
assessment both at diagnosis (100% overexpressing WT1)
and at the pre-SCT workup (immediately before starting
the conditioning regimen). At the pretransplantation
workup, 33 patients were WT1-negative (WT1 !250
copies) and 21 were WT1-positive (WT1 O250 copies).
Overall, the post-allo-SCT OS was significantly better in
WT1-negative patients at the time of SCT compared with
WT1-positive patients, with a median OS not reached in
the WT1-negative group and of 10.2 months in the
WT1-positive (log–rank p 5 0.0005; HR 5 3.7, 95%
CI 5 1.5–9; Fig. 2A). Similarly, the post-allo-SCT DFS
was significantly better in patients WT1-negative at the
time of transplantation compared with WT1-positive pa-
tients, with a median DFS not reached in the WT1-negative
group and of 5.5 months in the WT1-positive group (log–
rank p 5 0.0001; HR 5 4.38, 95% CI 5 1.9–10; Fig. 2B).
In addition, after stratification of the patients into three
groups, 33 of 54 cases (61%) were both in cCR and molec-
ular remission at the time of transplantation (group 1: cCR
and WT1 !250 copies/104 Abl), 13/54 (24%) cases were
in cCR but not in molecular remission (group 2: cCR and
WT1O250 copies/104 Abl), and 8/54 (15%) cases showed
a cytological evidence of disease with resistant or relapsed
AML (group 3). At the time of transplantation, the WT1
mean value in these three groups was 76 6 71 copies,
1632 6 1918 copies, and 8003 6 11920 copies, respec-
tively (Table 4). We underscore that, according to this strat-
ification, a significantly lower OS and DFS were observed
in patients with active disease (refractory or relapsed) and
in those with cCR but not molecular remission (groups 2
and 3) compared with patients with both cCR and
WT1-negative (group 1) at SCT (log–rank, p ! 0.001;
Fig. 3A and B).
The probability of post-allo-SCT relapse in the entire pa-
tient population at 12 and 24 months was 25% and 30%,
respectively and was significantly lower (9%) in patients
in cCR þ molecular remission (group 1) at the time of
transplantation compared with the other two groups (54%
in group 2 and 62.5% in group 3; log–rank p ! 0.001;
Fig. 4 and Table 4).
In addition, all group 2 and 3 (both WT1-positive) cases
that did not relapse after transplantation (9/24) achieved
and maintained WT1 negativity after transplantation. In
the 12/24 WT1-positive patients who relapsed, the WT1
trend was different: in 5/12 cases, the WT1 expression re-
mained positive after transplantation until cytological
relapse; in another 5/12 cases, the WT1 expression became
negative from 1 to 2 months after reinfusion and then went
back to positive; in other 2/12 cases, it was not evaluable. In
the five patients who reverted to positive after a posttrans-
plantation WT1 negativity, the time from transplantation to
WT1 overexpression and the speed of copy number in-
crease of WT1 were extremely variable from case to case.
Table 3. Outcome after allo-SCT (N 5 62 patients)
Follow-up, Months, Mean 6 SD 39 6 40
Follow-up, Months, Median (Range) 18 (1–130)
Status
Alive 34/62 (55%)a
Deceased 28/62 (45%)
TRM 14/62 (23%)
Cause of Death
AML Relapsed/Refractory 14/28
TRMb 14/28
!3 Months after SCT 5/14
3–12 Months after SCT 4/14
O12 Months after SCT 5/14
allo-SCT 5 allogeneic stem cell transplantation; cCR 5 cytological com-
plete remission; GVHD 5 graft versus host disease; SD 5 standard devi-
ation; TRM 5 transplantation-related mortality.
a31/34 in cCR.
bSeven GVHD, five infections, one acute myocardial infarction, and one
esophageal carcinoma.
Figure 1. (A) OS after allo-SCT; median OS 5 79 months. Probability of OS at 12 and 36 months 5 70% and 62%, respectively. (B) DFS after allo-SCT;
median DFS 5 58 months. Probability of DFS at 12 and 36 months 5 63% and 57%, respectively.
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In the 54 patients with WT1 levels available both at
baseline and pre-allo-SCT, the following pre- and post-
allo-SCT variables were included in a common multivariate
model: cytogenetic–molecular risk (high vs intermediate),
FLT3 mutation type (ITD vs TKD-D835), status at trans-
plantation (cCR þ WT1 !250 vs cCRþ WT1 O250 or
relapse/refractory), EBMT risk score (#4 vs O4), stem
cell source (marrow vs peripheral blood), conditioning
regimen (myeloablative vs not myeloablative), aGVHD
(grade !II vs grade OII), and cGVHD (presence vs
absence). The analysis showed that DFS was affected
only by the status of cCR þ WT1-negative (WT1 !250
copies) at the time of transplantation (p 5 0.0001,
HR 5 6.21, 95% CI 5 2.46–15.66), and also by a grade!
II aGVHD (p 5 0.011, HR 5 3.35, 95% CI 5 1.31–8.52).
Similarly, the only two variables found to independently in-
fluence the OS after allo-SCT were the status of
cCR þ WT1-negative at transplantation (p 5 0.0078,
HR 5 3.82, 95% CI 5 1.43–10.18) and the aGvHD
grade !II (p 5 0.028, HR 5 3.05, 95% CI 5 1.13–8.21;
Table 5).
Discussion
AML is a highly heterogeneous disease both from a pheno-
typical and a molecular–genetic point of view. It is now
clear that, even in the context of a single patient, AML con-
sists of different leukemic subclones, each with particular
biological characteristics and a different proliferation
pattern, as well as different survival and sensitivity to
chemotherapy [4]. FLT3 mutation represents a clear
example of this heterogeneity. In fact, not only is this mu-
tation present in approximately 20–30% of AML cases, but
in the context of individual cases, it can also have a
different level of intensity from the diagnosis and during
the course of the disease due to the expression of leukemic
subclones [1,3,4,8]. The presence of the FLT3 mutation is a
poor prognostic factor in AML patients with a high risk of
relapse and short duration of remission [1,3,4,8]. In addi-
tion, some recent studies emphasize the prognostic impor-
tance of the FLT3 allelic burden (allelic ratio); in
particular, an allelic ratio higher than 0.5–0.8 could be asso-
ciated with a negative prognostic effect determined by the
mutation [2,8,25,26]. It is noteworthy that, even if all of
Figure 2. (A) OS and (B) DFS after allo-SCT according to WT1 levels before allo-SCT (WT1-negative vs WT1-positive). For (A), WT1-negative patients,
median OS was not reached; for WT1-positive patients, median OS 5 10.2 months (log–rank p 5 0.0005, HR 5 3.7, 95% CI 5 1.5–9). For (B), WT1-
negative patients, median DFS was not reached; for WT1-positive patients, median DFS 5 5.5 months (log–rank p 5 0.0001, HR 5 4.38, 95%
CI 5 1.9–10); for WT1-negative patients, 5-year probability of OS and DFS: 70% and 67%, respectively.
Table 4. Relapse rate after allo-SCT according to WT1 expression and cytologic status at transplantation in 54 cases with quantitative WT1 expression
available both at diagnosis and at pre-allo-SCT workup
n Mean WT1 6 SD Median WT1 (range)
Relapse
Rate
FLT3-Positive Patients with WT1 Overexpression at AML Diagnosis 54/54 (100%) 9747 6 8064 7493.5 (454–33563) 15/54 (28%)
AML Status at Allo-SCT
cCR and Molecular Remission (WT1 !250 copies) 33/54 (61%) 76 6 71 55 (10–245) 3/33 (9%)a
cCR But Not Molecular Remission (WT1 O250 copies) 13/54 (24%) 1632 6 1,918 688 (305–6672) 7/13 (54%)a
Refractory or Relapsed AML 8/54 (15%) 8003 6 11920 2706 (1375–36423) 5/8 (62.5%)
allo-SCT5 allogeneic stem cell transplantation; AML5 acute myeloid leukemia; cCR5 cytological complete remission; FLT35 FMS-like tyrosine kinase
3; SD 5 standard deviation; WT1 5 Wilms’ tumor.
ap 5 0.0024 for comparison (Fisher’s exact test).
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the studies had not confirmed this cut-off, the idea that
FLT3-positive AMLs are not all prognostically equivalent
(due to different allelic burden, length of mutation, inser-
tion site, etc.) is being consolidated and, in this context,
FLT3-positive AMLs with high allelic burden would be
associated with a higher risk of relapse [8,26,27]. However,
quantitative rather than qualitative assessment of FLT3 has
been adopted recently, but it is not yet performed routinely.
Even in our cases, especially in patients being diagnosed
and receiving transplantations before 2010, only qualitative
FLT3 analysis was available because semiquantitative eval-
uation (allelic burden), calculated by analysis of capillary
electrophoresis, was not yet available in our center.
Another important aspect about FLT3 is its possible
role as a marker of MRD. Several studies have confirmed
that FLT3 is not a good marker of MRD because
leukemic relapse can result from a FLT3-negative sub-
clone [8]. In particular, FLT3 is still considered an inad-
equate MRD marker both because its expression is
unstable and because the available detection methods
(mainly PCR) have a limited sensitivity (maximum 5%
sensitivity); conversely, the most recent and sensitive
detection methods (such as next-generation sequencing)
are still not widespread and must be validated carefully
[8,28]. In absence of newer standardized methods, it is
difficult to monitor molecular MRD properly after
Figure 3. (A) OS and (B) DFS after allo-SCT according to remission status at transplantation (cCR and molecular remission, cCR but not molecular remis-
sion, refractory or relapsed AML).
Figure 4. Probability of relapse after allo-SCT according to disease status at transplantation (cCR and molecular remission, cCR but not molecular remis-
sion, refractory/relapsed AML; log–rank test between group 1 and groups 2–3, p ! 0.0001).
30 A. Candoni et al./ Experimental Hematology 2017;49:25–33
chemotherapy and after transplantation with this specific
marker [8].
Regarding the role of allo-SCT in FLT3-positive AML
patients, several studies, mostly retrospective and/or from
registries, showed a clear benefit of allo-SCT in FLT3-
mutated patients, especially if the transplantation is
performed in first CR [8,11,12,14,26,29,30]. A recent
meta-analysis, published in 2015, confirmed the efficacy
of allo-SCT in terms of OS, DFS, and relapse rate in
FLT3-positive patients compared with patients consoli-
dated with chemotherapy or undergoing autologous
transplantation (OR 5 1.55, 95% CI 5 1.33–1.82,
p ! 0.00001) [16]. In addition, a recent study from the
M.D. Anderson Cancer Center group pointed out that
allo-SCT is effective in FLT3-mutated AML patients
regardless of the FLT3 allelic ratio at diagnosis; however,
in this study, no outcome according to MRD stratification
at SCT was reported [31]. In summary, the more recent
literature data regarding allo-SCT in FLT3-mutated
AML patients confirm its efficacy (regardless of FLT3
allelic ratio at diagnosis) and the expected survival of
these patients, especially of those receiving transplanta-
tion in first cCR, is comparable to that of FLT3-
negative patients undergoing allo-SCT [8,31,32]. Howev-
er, it should be underscored that actual specific data on
the prognostic impact of molecular MRD at the time of
transplantation in FLT3-positive patients are not yet
available.
In our case series consisting of 62 FLT3-positive AML
patients, mostly (84%) in cCR at the time of allo-SCT,
we found a median OS of 79 months (with a 12- and
36-month OS of 70% and 62%, respectively) and a median
DFS of 58 months (with a 12- and 36-month DFS of 63%
and 57%, respectively); these data are in agreement with
those reported by a recent review and by the National
Marrow Donor Program in 2016 (OS 60% at 12 months
and 49% at 36 months) and support the role of allo-SCT
in overcoming the unfavorable prognostic FLT3 effect
[33,34].
Furthermore, in our population, we have verified the pre-
dictive value of molecular MRD, checked at the time point
of transplantation, for prediction of post-allo-SCT outcome.
Due to the fact that FLT3 is not currently considered an
optimal molecular MRD marker, we evaluated the post-
allo-SCT outcomes and the risk of relapse related to the
pre-allo-SCT levels of expression (not mutation) of the
pan leukemic MRD marker WT1. It is well known that
the WT1 gene is expressed inO90% of AML cases at diag-
nosis and it is stable over time; in addition, standardized
quantitative methods for its expression detection are avail-
able [18]. Therefore, expression of WT1 is currently
considered an adequate and reliable marker for monitoring
molecular MRD in the postchemotherapy and post-SCT
phase [18,35,36]. However, it is documented that, in the
post-allo-SCT phase, the time to recurrence of this MRD
marker relative to the subsequent cytological relapse can
be variable and, if overexpression of WT1 is too close to
cytological relapse, an early and effective preemptive ther-
apy may be unworkable [36]. In this respect, the WT1 pre-
SCT expression evaluation could be more helpful. Howev-
er, no data are available regarding the predictive value of
WT1 levels of expression in bone marrow samples
collected at the pre-allo-SCT time point.
In our series, 54 patients (87%) had a valuable of WT1
level both at diagnosis and at the time of transplantation
(preconditioning). All of these 54 cases overexpressed
WT1 at diagnosis (mean 9747 6 8064 copies). Comparing
post-allo-SCT OS and DFS of the patients overexpressing
and not overexpressing WT1 at the pre-SCT time point
(WT1-positive and WT1-negative cases), we noted a statis-
tically significant difference in favor of the WT1-negative
patients, both for OS (log–rank p 5 0.0005, HR 5 3.7,
95% CI 5 1.5–9) and DFS (log–rank p 5 0.0001,
HR 5 4.38, 95% CI 5 1.9–10) (Fig. 2A and B). Further,
stratifying the 54 WT1-monitored patients into three clas-
ses according to pre-SCT status (group 1 5 patients with
cCR þ molecular remission-WT1-negative; group 2 5 pa-
tients with cCR but not molecular remission-WT1-positive;
Table 5. Cox regression analysis of variables affecting DFS and OS after allo-SCT in FLT3-positive AML
Covariate
OS DFS
HR 95% CI p HR 95% CI p
Molecular-Cytogenetic Risk (High vs Intermediate) 2.41 0.462–12.564 0.29 1.28 0.324–5.053 0.72
FLT3 Mutation (ITD vs D835) 0.39 0.067–2.24 0.29 0.63 0.148–2.695 0.53
Cytologic þ Molecular CR (WT1 !250 Copies) 3.82 1.430–10.182 0.0078 6.21 2.465–15.667 0.0001
EBMT Risk Score (!4 vs O4) 0.83 0.237–2.949 0.78 0.48 0.139–1.712 0.26
Conditioning Regimen (Myeloablative vs Not Myeloablative) 1.02 0.384–2.730 0.96 0.1 0.407–2.433 0.99
Stem Cell Source (BM vs PB) 1.02 0.369–2.730 0.96 1.57 0.639–3.869 0.32
aGVHD (Grade !2) 3.05 1.134–8.213 0.028 3.35 1.317–8.529 0.011
cGVHD (Present vs Absent) 0.50 0.161–1.598 0.24 0.39 0.126–1.205 0.1
aGVHD 5 acute graft versus host disease; allo-SCT 5 allogeneic stem cell transplantation; AML 5 acute myeloid leukemia; BM 5 bone marrow;
cGVHD 5 chronic graft versus host disease; CR 5 complete remission; DFS 5 disease-free survival; EBMT 5 European Society for Blood and Marrow
Transplantation; FLT3 5 FMS-like tyrosine kinase 3; ITD 5 internal tandem duplication; OS 5 overall survival; PB 5 peripheral blood; SD 5 standard
deviation; WT1 5 Wilms’ tumor.
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and group 35 patients with cytological evidence of disease
at transplantation-refractory or relapsed), the excellent
outcome of patients in group 1 was still more evident
(5-year OS and DFS of 70% and 67%, respectively),
showing that, in FLT3-positive patients, it is possible to
discriminate, through pre-SCT quantitative analysis of
WT1, a subset (both in cCR and WT1-negative) with a
post-allo-SCT excellent outcome and low probability of
relapse (9% of relapse rate in group 1 of our series;
Fig. 3A and B and Table 4).
Furthermore, it was possible to identify a second subset
of FLT3-positive AML patients at allo-SCT (cCR but still
WT1-positive at transplantation, group 2) for whom the
post-allo-SCT outcome was extremely unfavorable (median
DFS of 8 months) and comparable to that of patients with
cytological active disease at the time of transplantation
(median OS and DFS of 7 and 5 months, respectively).
For group 2 patients with positive molecular WT1-MRD,
in which most relapses occurred within 12 months from
allo-SCT, it could be possible to consider a more compre-
hensive transplantation strategy, including a relapse pro-
phylaxis with targeted treatments such as FLT3
inhibitors 6 donor lymphocyte infusion or demethylating
agents, to be started before allo-SCT in order to obtain
MRD negativity (WT16 FLT3) or as soon as possible after
the allo-SCT procedure. This important predictive role of
the WT1 expression at time of transplantation in FLT3-
positive AML was also confirmed by the multivariate anal-
ysis, in which only the expression amount of WT1 at trans-
plantation and the post-SCT development of mild aGVHD
were the significant factors (Table 5).
In summary, the data obtained from the present popula-
tion (62 FLT3-positive AML patients undergoing allo-SCT
at our department of hematology in the last 11 years)
confirmed the ability of allo-SCT to overcome the unfavor-
able prognostic impact of FLT3 mutations. Moreover, our
data emphasize the importance of molecular MRD status
at the time of transplantation in predicting the outcome
and risk of post-allo-SCT relapse and support the recently
published data by the Fred Hutchinson Cancer Research
Center group, which used a phenotypic analysis (LAIP)
as MRD to stratify the patient risk in the pre-SCT setting
[37]. In our case, the use of WT1 gene expression as a mo-
lecular marker of MRD before transplantation allowed us to
optimally stratify FLT3-positive AML patients, showing
how the post-allo-SCToutcome is very favorable in patients
with cytologic and molecular remission (both in cCR and
WT1-negative) in the pre-SCTworkup; conversely, patients
with cCR who were not in molecular remission (WT1-
positive and MRD-positive at the time of allo-SCT) have
an extremely unfavorable post-allo-SCT outcome. For these
patients, considering the increasing availability of FLT3 in-
hibitors (sorafenib, midostaurin, quizartinib, lestaurinib,
etc), a more comprehensive strategy involving a prophylac-
tic use of these drugs also in the post-allo-SCT phase
should be considered in order to reduce the high but pre-
dictable incidence of relapses [32,38].
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